Clinical management of patients with malignant tumours has dramatically changed over the last several years with the introduction of novel therapeutics such as receptor-targeted therapies, downstream effectors, and antiangiogenic compounds. Monitoring the response to these targeted therapies requires a combined imaging approach utilizing both functional and structural techniques.

From well-established morphological and functional imaging techniques, to novel fusion imaging modalities, our radiologists will deliver high quality, broad proficiency across disease type and imaging interpretation criteria.